Breast cancer resistance protein (BCRP), also known as mitoxantrone resistance protein (MRX) or placenta ABC protein (ABC-P), is the second member of the ABCG subfamily of ABC transport proteins (gene symbol ABCG2). Transfection and enforced expression of BCRP in drug-sensitive cells confers resistance to mitoxantrone, doxorubicin, daunorubicin and topotecan. In this study the expression of BCRP gene was measured using TaqMan real-time PCR in 59 children with newly diagnosed AML. Nine patients were also analyzed in relapse. The median of BCRP gene expression was more than 10 times higher in patients who did not achieve remission after the first phase of chemotherapy (n ‫؍‬ 24) as compared to patients who did achieve remission at this stage (n ‫؍‬ 21; P ‫؍‬ 0.012). In first relapse the expression of the BCRP gene was higher than at diagnosis (P ‫؍‬ 0.038). Although high levels of BCRP gene expression were more frequent in subtypes of AML with a favorable prognosis, we found that within both risk groups (high and low risk), patients who expressed high levels of BCRP had a worse prognosis (P ‫؍‬ 0.023). Our results strongly suggest that the expression of the BCRP gene reduces the response to chemotherapy in AML and that BCRP expression is higher at the time of relapse.
Introduction
A major issue in the treatment of acute myeloid leukemia (AML) is the development of resistance to chemotherapeutic drugs. While more than 80% of children with AML may initially achieve complete remission with current therapeutic regimens, a large number of these patients relapse with resistant disease; even with aggressive therapy, the event-free survival rate is only about 50%. 1, 2 The proteins of the adenoside-triphosphate-binding (ABC)-superfamily of transporters have the ability to function as outward pumps for chemotherapeutic drugs. 3 Their expression in AML has been studied intensively to achieve a better understanding of the mechanisms that lead to drug resistance in this disease. Many studies have indicated that overexpression of P-glycoprotein which is encoded by the MDR1 gene is associated with a poor response to chemotherapy and low overall survival. [4] [5] [6] [7] However, this does not seem to apply to childhood AML. 8 The multidrug resistance protein 1 (MRP1) was shown to be expressed at higher levels at disease relapse as compared to presentation, 9, 10 but large studies have been unable to detect any relationship between MRP expression and clinical response in AML. 4, 11 Sauerbrey et al 12 showed that the outcome for children with AML was poorer the higher the number of coexpressed resistance-related proteins.
The most recently identified member of the family of ABC transporters is the breast cancer resistance protein (BCRP) which was isolated from multidrug-resistant MCF7/ADRVp breast cancer cells. [13] [14] [15] [16] BCRP is encoded by the ABCG2 gene which was mapped to chromosome 4. 15 The protein consists of 655 amino acids and the molecular weight is 72.6 kDa. 16 It has only one ATP-binding cassette and six putative transmembrane domains, suggesting that BCRP is a half-transporter. 17 High expression of BCRP has been described in drugresistant ovary, breast, colon, gastric cancer and fibrosarcoma cell lines, as well as placental tissue, endothelium of veins and capillaries, epithelium of colon and small intestine and bile canaliculi. 18 Ross et al 19 found relatively high levels of the BCRP gene in seven out of 20 adult patients with AML. Sargent et al 20 showed that cells from patients with AML are less sensitive to daunorubicin in vitro when expressing BCRP. The aims of our study were to find out whether the BCRP gene is also expressed in childhood AML and whether it is associated with a poor response to chemotherapy.
Patients and methods

Patients and therapy
All 59 patients were under 20 years of age and diagnosed with previously untreated AML. The main patient characteristics All studies included induction therapies with cytosine-arabinoside, anthracycline and thioguanine or etoposide followed by bone marrow transplantation or intensive consolidation protocols with prophylactic CNS-irradiation and maintenance therapy. The event-free survival after 5 years was 34% in AML-I/82, 43% in AML-II/87, 21 and 51% in AML-BFM-93. 1 Definite results for AML-BFM-98
are not yet available. Patients were stratified into high and low risk according to our recently described risk factor for children with AML. 22 This risk factor is calculated for each patient using an equation that includes the variables white blood count, FAB-type, Auer rods, cytogenetics and response status on day 15. In this study, the variable 'response on day 15' was excluded because it is only useful in patients who receive exactly the same therapy.
Healthy donors
Samples of mononuclear cells (MNC) of peripheral blood from healthy donors were donated by laboratory staff. CD34
+ stem cells and MNC of bone marrow were obtained from healthy adults who donated for bone marrow transplantation. Written consent was given for the use of these samples for this study.
Sample collection and processing
Leukemic cells and mononuclear cells of healthy donors were isolated from bone marrow or peripheral blood by FicollHypaque density gradient centrifugation. After this procedure the percentage of leukemic cells was more than 80% in all patient samples as determined by May-Grü nwald-Giemsa stained smears. CD34 + stem cells of healthy donors were isolated using Clinimacs System (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the stem-cell population was more than 95% determined by flow cytometry.
All samples were cryopreserved in liquid nitrogen with 10% dimethylsulphoxide and 5% fetal calf serum. Total RNA was isolated using RNeasy Mini Kit including DNase digestion (Qiagen, Hilden, Germany) following the manufacturer's instructions. The amount of RNA was measured by photometry and a stock solution of 1 g RNA in 40 l was prepared. RNA was transcribed into cDNA using Omniscript (Qiagen).
In addition to the patient samples, we also analyzed BCRP gene expression in five cell lines; three with promyelocytic differentiation (KG1, HL60 and HL60VR), one with monocytic differentiation (U937) and one from a patient with chronic myeloid leukemia (K526).
A pool of cDNA from the BCRP expressing breast cancer cell line MCF7 was prepared as reference.
Quantitative real-time PCR
Quantitative PCR was performed using the ABI Prism 7700 Sequence Detector (Applied Biosystems, Weiterstadt, Germany) according to the manufacturer's instructions. PCR primers used for the analysis of BCRP expression (gene symbol ABCG2; accession No. AF098951) were BCRP1370F (forward primer: 5Ј-AGA TGG GTT TCC AAG CGT TCA T-3Ј) and BCRP1460R (reverse primer: 5Ј-CCA GTC CCA GTA CGA CTG TGA CA-3Ј). The TaqMan probe BCRP1401T (5Ј-TGC TGG GTA ATC CCC AGG CCT CTA TAG C-3Ј) was labeled with FAM. Amplicon length was 91 bp. Final concentration of primers was 900 nM, final concentration of the TaqMan probe was 300 nM.
BCRP expression was standardized for expression of beta-2-microglobulin. This was measured using Pre-Developed Assay Reagents (PDAR) for beta-2-microglobulin (Applied Biosystems) according to the manufacturer's instructions.
All samples were analyzed in triplicate. The variation of the triplicate measurements was extremely small, compared to the variation between different samples. In the few cases where there was a substantial difference between the three values, the sample was re-analyzed.
The final volume was 50 l, including 2 l of the investigated sample. Universal PCR Master Mix (Applied Biosystems) was used according to the manufacturer's instructions.
Serial dilutions of cDNA of the cell line MCF7 were used to generate standard curves and the expression of BCRP in all samples was calculated in relation to this cell line. The threshold cycles for the undiluted stock solution of MCF7-cDNA was 29 for BCRP (threshold ϭ 0.02) and 24 for beta-2-microglobulin (threshold ϭ 0.06).
Statistical methods
The probability of overall survival was calculated according to the method of Kaplan and Meier. Log-rank tests were calculated to estimate the significance of differences in rates of survival. Since the levels of BCRP expression did not follow a normal distribution, expression of BCRP in different groups of patients was compared using the Mann-Whitney test for two groups and the Kruskal-Wallis test for more than two groups. The correlation between BCRP expression and other pretherapeutic findings was investigated by means of Spearman's correlation coefficient and the BCRP expression at presentation and at relapse was compared using the Wilcoxon test. All P values are given for two-sided tests. All calculations were performed with the SPSS 8.0 program.
Results
Expression of BCRP in childhood AML
We retrospectively analyzed the expression of BCRP gene in 59 children with newly diagnosed AML. The highest relative BCRP expression was 0.049; the median was 0.0018. The level of expression of all patients is shown in Figure 1 . BCRP expression varied about 40-fold from the 25th percentile to the 75th percentile.
In order to investigate the association between BCRP expression and response to therapy, we selected all patients who had received the full induction therapy in their respective study and were investigated for remission status before the beginning of the next therapy phase. Six patients died of early complications without undergoing full induction therapy. In eight patients, data on remission status prior to the second therapy phase were not available. Of the remaining 45 patients, 21 achieved remission after induction therapy, ie less then 5% leukemic cells in bone marrow in the presence of recovering hematopoiesis, and 24 patients did not. Box plots of both groups are shown in Figure 2 . The median of BCRP expression in the group without remission was 10 times higher than the median in the group that achieved remission (P ϭ 0.012).
Nine patients were analyzed at initial stage as well as first relapse. As shown in Figure 3 , BCRP expressions were much higher at relapse (P ϭ0.038).
When using the median of BCRP expression as cut-off for high and low expression, we found no difference in overall survival between the groups. However, this might be a misleading result because we also found that BCRP expression was higher in patients with favorable subtypes of AML. BCRP expression was unevenly distributed among the different FAB types (P ϭ 0.004) with high levels in M1 and M2 (median ϭ 0.0055 and 0.0022) and the lowest levels in M5 (median ϭ 0.00045). This is in keeping with the finding that patients with Auer rods, which are mainly found in M1 and M2, expressed much higher levels of BCRP (median ϭ 0.010) than patients without Auer rods (median ϭ 0.0013; P ϭ 0.002). There was an inverse correlation between BCRP expression and initial white blood count (P ϭ 0.017; Spearman's correlation coefficient ϭ Ϫ0.31). BCRP expression was not associa-
Figure 2
Box plots (5th, 25th, 50th, 75th and 95th percentile) of BCRP expression in patients who did not achieve remission after receiving full induction therapy and in patients who achieved remission after induction therapy. Mann-Whitney test: P ϭ 0.012.
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Figure 3
BCRP expression at initial stage and relapse in nine children with AML. Wilcoxon test: P ϭ 0.038. ted with age, sex, percentage of leukemic cells in blood or bone marrow, enlargement of liver or spleen, inversion inv(16), translocation t(8;21) or CNS involvement.
A variable that is found more often in patients with favorable subgroups of a disease may still be a negative prognostic parameter within each subgroup. In order to investigate this, our recently described risk factor for children with AML, 22 was calculated for all 50 patients for whom the required data were available. Patients were then grouped into 25 patients with high risk factors and 25 patients with low risk factors. Figure  4 shows that there was a higher proportion of patients with high levels of BCRP in the low risk group. However, within both risk groups high BCRP expression was associated with worse overall survival. When calculating the log rank test for high expression of BCRP vs low expression, with the risk group as a stratification variable, the P value was 0.023.
Expression of BCRP in cell lines
Relative BCRP expression was analyzed in five cell lines. The levels were 0.049 in K562, 0.00014 in U937, 0.0088 in HL60, 0.0080 in HL60AR and 0.0010 in KG1.
Expression of BCRP in samples of healthy donors
BCRP expression was also analyzed in five samples of mononuclear cells (MNC) of blood, four samples of MNC of bone marrow and three samples of CD34 + stem cells. The expression in CD34 + stem cells was high (0.037/0.052/0.031). The expression of BCRP in blood and bone marrow showed a larger variability with levels from 0.00056 to 0.0081 in blood and from 0.0087 to 0.083 in bone marrow.
Discussion
In this study we provide the first evidence that the expression of the BCRP gene in AML is associated with a poor response BCRP expression and overall survival in high and low risk patients. The median was used as cut off for the risk factor, as well as the BCRP expression. Log rank test for high expression of BCRP vs low expression with the risk group as stratification variable: P ϭ 0.023. N, number of patients; OS, overall survival; SE, standard error.
to remission induction therapy. Remission status before the second phase of chemotherapy is a simple parameter for therapy response and was available for most of our patients. Since in each of the four studies BCRP expression was higher in the group that did not achieve remission after induction therapy, it is very unlikely that this finding was biased by differences between the induction therapies in the four studies.
Patients who died of early complications without receiving full induction therapy were excluded because these complications, for instance sepsis or bleeding disorders, are not usually caused by poor response to therapy. In fact, if patients die from tumor lysis syndromes it might even be caused by a strong response to chemotherapy. However, when those six patients were included with the group that did not achieve remission, the significance was even higher (P ϭ 0.009).
Our results also show that BCRP expression is significantly elevated at the time of relapse. This too, suggests that BCRP is involved in drug resistance in AML, and that leukemic cells with higher expression of BCRP are more likely to survive therapy and cause relapses.
BCRP expression was significantly higher in subgroups of patients with favorable prognostic features, but our results suggest that BCRP expression is an adverse prognostic parameter when comparing patients with similar risk factors. These results need to be interpreted with caution because of the small number of patients in the subgroups and because patients were treated within different studies with varying overall results. However, the expression of BCRP as well as the risk factor were evenly distributed among the four studies, making a bias less likely. Our risk factor was used because it allowed the definition of a high and a low risk group with equal numbers of patients. When using other known risk group definitions, at least one subgroup was too small to allow any comparisons.
The levels of BCRP expression in MNC of normal blood were similar to those found in patient samples, whereas MNC of bone marrow and CD34
+ stem cells seem to express even higher amounts. Further studies, including functional assays, are necessary to find out whether it is possible to sensitize AML cells to chemotherapy by blocking the function of BCRP without sensitizing the normal hematopoietic system at the same time.
